Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Apple Turns 50: From Garage Startup to AI Crossroads 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
NEWARK, Calif., Nov. 22, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will participate in a fireside chat at the 28th Annual Piper Jaffray Healthcare Conference scheduled for 2:00 pm ET (11:00 am PT) on Tuesday, November 29, 2016 in New York, New York.
The fireside chat will be webcast live and may be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the event will be archived for 30 days on the company's website.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
